Plus Therapeutics Inc. announced a significant private placement agreement with various purchasers, under which it issued 4,069,738 shares of common stock and prefunded warrants for up to 23,972,400 shares of common stock. Additionally, Series A Warrants for up to 280,421,380 shares and Series B Warrants for up to 1,261,896,210 shares were also part of the issuance. In an effort to minimize dilution, the company entered into a letter agreement with the purchasers to return a portion of the securities, cancel all Series A Warrants, and amend the Series B Warrants to reduce the number of shares issuable and adjust exercise ratios.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.